Forskningsprofil
Størstedelen av forskningsaktiviteten er relater til inflammatorisk tarmsykdom (IBD), men det forskes også på cøliaki og leversykdommer. Vi er involvert i basalforskning, så vel som klinisk forskning og medikamentutprøving i diverse legemiddelstudier. I basalforskningen fokuserer vi på prognostiske faktorer for sykdomsforløp og behandlingseffekt, samt mekanismer bak utvikling av IBD-relatert tarmkreft. I kliniske studier ser vi på effekten av medikamentmålinger ved biologisk behandling, behandling med intravenøst jern, mikrobiotas rolle og ekstrakorporal fotoferese som fremtidig behandlingsmulighet.
Forskningsprosjekter – IBD-relaterte
- IBD-CHARACTER: A multi-modal integrated biomarker study (IBD-Character Consortium) funded by EU´s 7th Framework Program.
- NOR-DRUM: A NORwegian multicentre randomised controlled trial assessing the effectiveness of tailoring infliximab treatment by therapeutic DRUg Monitoring.
- Nor-vaC: Prospective, observational study to evaluate immunogenicity and safety following SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases receiving immunosuppressive therapy.
- Colorectal neoplasia in IBD: A prospective study comparing endoscopic surveillance with regular clinical follow-up.
- Photopheresis in the treatment of patients with Crohns’ disease using 5-aminolevulinic acid.
- Gut microbiota – its relation to clinical outcome and mucosal barrier functions in IBD.
- Clinical implementation and safety of high dose i.v. iron treatment in gastroenterology.
- IBSEN II: This is a multi-center study, including five hospitals in the Helse Sør-Øst region, which has included 321 adult and pediatric IBD patients and controls.
- IBSEN III: This is a multi-center study, including 20 hospitals in the Helse Sør-Øst region, with the aim to include 2400 adult and pediatric IBD patients and controls.
- Inflammatory bowel disease and persistent organic pollutants (POPs): A translational research approach.
- Molecular drivers and inhibitors of colorectal cancer in IBD. This project is a close collaboration with Hilde Nilsen group at EpiGen Institute Ahus. different stages of carcinogenesis in IBD.
- Identification of predictive biomarkers for personalised treatment of patients with Crohn’s disease. Single cell RNA sequencing (scRNAseq) and spatial transcriptomics.
- BLUE study: Incidence, treatment and outcome of gastrointestinal bleeding due to peptic ulcers and erosions.
- Clinical trials. The unit has a high activity in conducting clinical trials, both phase 2 and 3, initiated by the pharmaceutical industry to evaluate efficacy and safety for new medical treatments in IBD.
Leder: Jørgen Jahnsen, MD, PhD, professor og overlege, Akershus universitetssykehus Gastromedisinsk avdeling og UiO. E: jorgen.jahnsen@medisin.uio.no.
